BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

Core Insights - BriaCell Therapeutics Corp. presented promising clinical data at the 2025 ASCO Annual Meeting, showcasing the efficacy and safety of its Bria-IMT and Bria-OTS therapies in metastatic breast cancer [1][2][5] Clinical Data Summary - The Phase 2 study of Bria-IMT demonstrated a median overall survival of 17.3 months, which is superior to outcomes reported for comparable patients in existing literature [5][6] - The overall clinical benefit rate (CBR) in the Phase 2 study was 55%, with 100% CBR in HER2+ patients, 55% in HR+/HER2- patients, and 45% in triple-negative breast cancer (TNBC) patients [4][5] - The Phase 3 formulation of Bria-IMT showed significantly improved overall survival (13.9 months) compared to an alternate formulation [6][13] Safety Profile - The Bria-IMT regimen exhibited a low incidence of all-grade and grade 3/4 adverse events, with no treatment-related discontinuations reported [2][5][13] - 22% of patients are still in active survival follow-up, with one patient remaining on study for over 18 months [13] Ongoing Studies - BriaCell is conducting an ongoing pivotal Phase 3 trial (NCT06072612) comparing Bria-IMT to the treatment of physician's choice, with a focus on identifying patients who may benefit the most from the treatment [8][10] - A Phase 1/2 study of Bria-OTS is also underway, with initial results showing a confirmed resolution of a breast cancer lung metastasis in one patient [9]